About the Company
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Employees
45
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZSAN News
Zosano Appoints New Chief Financial Officer
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic ...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
From 2019 to 2022 Mr. Lo was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company. From 2015 to ...
Krishna Kittu Kolluri's Net Worth
Who is Krishna Kittu Kolluri? Krishna Kittu Kolluri has an estimated net worth of $565 Million. This is based on reported shares across multiple companies, which include TESARO, Inc., OPOWER, INC ...
Stella Pharma Corp Ordinary Shares 4888
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BCT:CA BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in ...
Nutra Pharma Corp. Reaches Settlement with SEC
CORAL SPRINGS, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Nutra Pharma Corporation (OTC: NPHC), (“Nutra Pharma” or the “Company”) reached a settlement with the U.S. Securities and Exchange ...
NervGen Pharma Corp.
Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...
RAMM Pharma Corp. Announces Corporate Update
TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the "Company" or "RAMM") (CSE: RAMM), is pleased to advise its shareholders that in ...
InnoCan Pharma Corp.
Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...
RAMM Pharma Corp. Announces Corporate Update
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM")(CSE:RAMM), announced its intention to ...
Loading the latest forecasts...